ClinicalTrials.gg
TerminatedNCT00652678Updated Oct 22, 2021

Predictive Blood Tests for Severe Radiation Reactions in Breast Cancer Patients

An observational study in Abnormalities, Radiation-Induced, sponsored by State University of New York - Upstate Medical University. Terminated at 1 site in United States. Open to female participants aged 48 Years and older. Per ClinicalTrials.gov, last updated 2021-10-22.

Sponsored by State University of New York - Upstate Medical University · Observational

How we know

Why this study was terminated
Lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
38
Ages
48 Years and older
Sex
Female
01

Study summary

Some patients who undergo breast cancer treatment with lumpectomy followed by radiation therapy develop significant late skin and soft tissue changes, resulting in a poor cosmetic outcome. The goal of this study is to try to predict severe tissue reactions by using a combination of three of the latest blood tests, one of which we have developed ourselves.

Read the detailed description

Three tubes of blood will be drawn from each subject. Two members of the study team will also independently assess each subject for the degree to which various radiation-induced soft tissue changes are evident. Subjects will be put into three groups according to the severity of the soft tissue changes which are noted, and the results of the blood tests for members of each group will be analyzed to determine whether a correlation with cosmetic outcomes can be determined. If the results are promising, they will be studied further and used as the basis for future prospective clinical trials.

02

Conditions studied

  • Abnormalities, Radiation-Induced

Browse trials for

Keywords

  • Breast cancer
  • Radiation effects
03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 38 is below the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

State University of New York - Upstate Medical University is the lead sponsor of 158 studies on the registry; 19 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 4 (36%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
48 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Potential study subjects will be drawn from patients with a history of treatment for breast cancer with lumpectomy followed by radiation therapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Breast cancer treatment: lumpectomy followed by external beam XRT to breast
  • Age at the time of radiotherapy treatment: 45-65 years old
  • XRT dose to breast: >/= 4500 and \</= 5200 cGy, fraction size 180 or 200 cGy
  • Dose distribution: no area receiving >/= 112% of prescribed dose
  • Follow-ups: patients must be >/= 2.5 years post-treatment

Exclusion criteria

Exclusion Criteria:

  • Reconstructive surgery to involved breast
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
38 participants (actual)
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. correlation of the results obtained from the three blood tests with the clinical assessments of cosmetic outcome for each subject

    Time frame: at least 2.5 years following lumpectomy and radiation therapy

07

Study locations

1 site
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2008
First posted
Apr 4, 2008
Start
Aug 2006
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Last update
Oct 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00652678
Collaborators
Carol M. Baldwin Breast Cancer Research Fund, Inc.
Responsible party
Sponsor
First posted
Apr 4, 2008
Start date
Aug 2006
Primary completion
Aug 2012
Completion
Aug 2012
Last update
Oct 22, 2021

Study contacts

Peter J Hahn, PhD
principal investigator · State University of New York - Upstate Medical University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion